Consolidated Statements of Earnings (USD $) In Millions, except Share data in Thousands, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Revenues:
Premiums, principally supplemental health insurance	$ 5,028		$ 5,660		$ 15,225		$ 16,505
Net investment income	821		869		2,467		2,597
Realized investment gains (losses):
Other-than-temporary impairment losses realized	(10)	[1]	(97)	[1]	(65)	[1]	(643)	[1]
Sales and redemptions	72		288		277		358
Derivative and other gains (losses)	(40)		95		167		108
Total realized investment gains (losses)	22		286		379		(177)
Other income	15		32		67		64
Total revenues	5,886		6,847		18,138		18,989
Benefits and expenses:
Benefits and claims	3,485		3,932		10,417		11,341
Acquisition and operating expenses:
Amortization of deferred policy acquisition costs	256		281		790		838
Insurance commissions	388		442		1,158		1,309
Insurance expenses	568		595		1,631		1,745
Interest expense	71		67		211		186
Other operating expenses	49		50		143		147
Total acquisition and operating expenses	1,332		1,435		3,933		4,225
Total benefits and expenses	4,817		5,367		14,350		15,566
Earnings before income taxes	1,069		1,480		3,788		3,423
Income taxes	367		463		1,305		1,138
Net earnings	$ 702		$ 1,017		$ 2,483		$ 2,285
Net earnings per share:
Basic	$ 1.51		$ 2.17		$ 5.34		$ 4.90
Diluted	$ 1.50		$ 2.16		$ 5.31		$ 4.87
Weighted-average outstanding common shares used in computing earnings per share (In thousands):
Basic	464,324		467,422		465,325		466,702
Diluted	467,391		469,721		468,052		468,951
Cash dividends per share	$ 0.35		$ 0.33		$ 1.05		$ 0.99

[1] Includes $0 and $70 for the three-month periods and $0 and $365 for the nine-month periods ended September 30, 2013 and 2012, respectively, for credit-related impairments; $0 and $27 for the three-month periods and $1 and $27 for the nine-month periods ended September 30, 2013 and 2012, respectively, for impairments due to severity and duration of decline in fair value; and $10 and $0 for the three-month periods and $64 and $251 for the nine-month periods ended September 30, 2013 and 2012, respectively, from change in intent to sell securities